Inflammatory Disease News and Research RSS Feed - Inflammatory Disease News and Research

Reducing insomnia can decrease inflammation, lower risk for chronic disease in older adults

Reducing insomnia can decrease inflammation, lower risk for chronic disease in older adults

Lack of sleep can make you sick. And while everybody has the occasional restless night, for those who suffer from chronic insomnia — some 15 percent of older adults in the United States — that sleep loss can increase the risk for cardiovascular disease, hypertension, weight gain, type 2 diabetes, and even lead to an earlier death. [More]
Researchers show how activation of receptor provokes bone degradation of rheumatoid arthritis

Researchers show how activation of receptor provokes bone degradation of rheumatoid arthritis

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis -- and that activation of this one receptor, found on cells in the fluid of arthritic joints, is all that is required. [More]
Study points to new therapeutic target to interrupt inflammation, bone erosion in rheumatoid arthritis

Study points to new therapeutic target to interrupt inflammation, bone erosion in rheumatoid arthritis

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis -- and that activation of this one receptor, found on cells in the fluid of arthritic joints, is all that is required. [More]
People with multiple sclerosis lose myelin in gray matter

People with multiple sclerosis lose myelin in gray matter

People with multiple sclerosis (MS) lose myelin in the gray matter of their brains and the loss is closely correlated with the severity of the disease, according to a new magnetic resonance imaging (MRI) study. [More]
Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin). [More]
Decision tool set to improve management of low back pain

Decision tool set to improve management of low back pain

Experts have developed an evidence-based tool to help doctors in secondary and tertiary care decide how best to manage patients with chronic low back pain, a condition with the highest societal burden in Western Europe. [More]
Reduce inflammatory reaction by losing weight, says researcher

Reduce inflammatory reaction by losing weight, says researcher

Researchers have found a possible molecular explanation for why overweight is harmful. This new knowledge may provide new drugs for heart attack, stroke, cancer and chronic intestinal inflammation. [More]
Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis. [More]
Physiological variables best predict adult asthma phenotypes

Physiological variables best predict adult asthma phenotypes

Physiological variables are more consistent predictors of adult asthma phenotypes than inflammatory biomarkers, an international team of researchers suggests. [More]
Scientists identify long-overlooked function of vascular smooth muscle cells in atherosclerosis

Scientists identify long-overlooked function of vascular smooth muscle cells in atherosclerosis

Scientists at the Interfaculty Institute of Biochemistry (IFIB) have collaborated with colleagues from the Department of Pharmacy and the Department of Dermatology of the University of Tübingen to identify a long-overlooked function of vascular smooth muscle cells in atherosclerosis. [More]
Black and Hispanic SLE patients are more likely to be readmitted than white patients

Black and Hispanic SLE patients are more likely to be readmitted than white patients

A new study reveals that one in six patients with systemic lupus erythematosus (SLE) is readmitted to the hospital within 30 days of being discharged. [More]
Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate has been approved since January 2014 for adults with relapsing remitting multiple sclerosis. [More]
Five-year $10.7M grant to study control, prevention of sexually-transmitted infections

Five-year $10.7M grant to study control, prevention of sexually-transmitted infections

The University of Maryland Schools of Dentistry (UM SOD) and Medicine (UM SOM) jointly announced today that they have received a five-year $10.7 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to study the causes, prevention and treatment of sexually-transmitted diseases (STDs). [More]
Researchers working to develop new drugs for treating chronic inflammatory diseases

Researchers working to develop new drugs for treating chronic inflammatory diseases

Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong. [More]
Information about female condom is necessary to communicate with young people

Information about female condom is necessary to communicate with young people

The female condom is one of just two barrier methods that can protect against sexually transmitted infections and unplanned pregnancies, yet many young adults are not aware of the device, a new study by two UT Arlington researchers has found. [More]
Scientists identify genes that may help predict steroid responsiveness in people with EoE

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils. [More]
Researchers develop world's first T-cell peptide-based vaccine for heart disease

Researchers develop world's first T-cell peptide-based vaccine for heart disease

Researchers at Wayne State University have made a fundamental discovery and, in subsequent collaboration with scientists at La Jolla Institute for Allergy and Immunology (LIAI), are one step closer to the goal of developing the world's first T-cell peptide-based vaccine for heart disease - the number one killer in the nation. [More]
NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

Scientists funded by the National Institutes of Health have identified genetic markers associated with eosinophilic esophagitis (EoE), an inflammatory disease characterized by high levels of immune cells called eosinophils in the esophagus. [More]
Acute glaucoma is largely an inflammatory disease, say researchers

Acute glaucoma is largely an inflammatory disease, say researchers

Researchers at the University of California, San Diego School of Medicine and Sun Yat-sen University in China have shown that acute glaucoma in mice is largely an inflammatory disease and that high pressure in the eye causes vision loss by setting in motion an inflammatory response similar to that evoked by bacterial infections. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]